These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Kulkarni HR; Singh A; Langbein T; Schuchardt C; Mueller D; Zhang J; Lehmann C; Baum RP Br J Radiol; 2018 Nov; 91(1091):20180308. PubMed ID: 29762048 [TBL] [Abstract][Full Text] [Related]
6. [PET/CT: Molecular Imaging and Theranostics for Radionuclide Therapy]. Derlin T; Bengel FM Pneumologie; 2017 Jan; 71(1):48-62. PubMed ID: 28114710 [No Abstract] [Full Text] [Related]
7. TheraP: a randomized phase 2 trial of Hofman MS; Emmett L; Violet J; Y Zhang A; Lawrence NJ; Stockler M; Francis RJ; Iravani A; Williams S; Azad A; Martin A; McJannett M; ; Davis ID BJU Int; 2019 Nov; 124 Suppl 1():5-13. PubMed ID: 31638341 [TBL] [Abstract][Full Text] [Related]
8. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091 [TBL] [Abstract][Full Text] [Related]
9. Molecular Imaging and Precision Medicine: PET/Computed Tomography and Therapy Response Assessment in Oncology. Sheikhbahaei S; Mena E; Pattanayak P; Taghipour M; Solnes LB; Subramaniam RM PET Clin; 2017 Jan; 12(1):105-118. PubMed ID: 27863562 [TBL] [Abstract][Full Text] [Related]
10. Evidence of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-PSMA-HBED-CC PET/CT. Verma P; Malhotra G; Agrawal R; Sonavane S; Meshram V; Asopa RV Clin Nucl Med; 2018 Aug; 43(8):e265-e268. PubMed ID: 29894335 [TBL] [Abstract][Full Text] [Related]
12. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer. Giovacchini G; Giovannini E; Riondato M; Ciarmiello A Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291 [TBL] [Abstract][Full Text] [Related]
13. An introduction to the clinical practice of theranostics in oncology. Turner JH Br J Radiol; 2018 Nov; 91(1091):20180440. PubMed ID: 30179054 [TBL] [Abstract][Full Text] [Related]
14. Theranostic in Nuclear Medicine - The paradigm of NET. Giammarile F Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562 [TBL] [Abstract][Full Text] [Related]
15. Nuclear Medicine Imaging Procedures in Oncology. Mohan AM; Beindorff N; Brenner W Methods Mol Biol; 2021; 2294():297-323. PubMed ID: 33742410 [TBL] [Abstract][Full Text] [Related]
16. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298 [TBL] [Abstract][Full Text] [Related]
17. [Theranostics and hybrid imaging for somatostatin receptor-expressing tumors]. Werner RA; Bengel FM; Derlin T Radiologe; 2020 May; 60(5):413-420. PubMed ID: 32052116 [TBL] [Abstract][Full Text] [Related]
18. 18F-FDG, 68Ga-DOTATATE and 68Ga-PSMA Positive Metastatic Large Cell Neuroendocrine Prostate Tumor. Acar E; Kaya GÇ Clin Nucl Med; 2019 Jan; 44(1):53-54. PubMed ID: 30325820 [TBL] [Abstract][Full Text] [Related]